 | • レポートコード：MRC2309A102 • 出版社/出版日：Transparency Market Research / 2023年7月31日 • レポート形態：英文、PDF、180ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| フラグメントベース創薬市場 - レポートの範囲TMRの調査レポート「世界のフラグメントベース創薬市場」は、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。2023年を基準年、2031年を予測年として、2017年から2031年までの世界のフラグメントベース創薬市場の収益を提供します。また、2023年から2031年までの世界のフラグメントベース創薬市場の複合年間成長率（CAGR %）も掲載しています。 本レポートは広範な調査を経て作成されました。主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。二次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、フラグメントベース創薬市場を把握しました。 二次調査には、インターネット情報源、政府機関の統計データ、ウェブサイト、業界団体なども含まれます。アナリストは、トップダウンアプローチとボトムアップアプローチを組み合わせて、世界のフラグメントベース創薬市場の様々な属性を調査しました。 本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、本レポートは、世界のフラグメントベース創薬市場における競争ダイナミクスの変化に光を投げかけています。これらは、既存の市場プレイヤーだけでなく、世界のフラグメントベース創薬市場への参入に関心のある企業にとっても貴重なツールとなります。 当レポートでは、世界のフラグメントベース創薬市場の競争環境について調査しています。世界のフラグメントベース創薬市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイリングされています。会社概要、財務状況、最近の開発状況、SWOTは、本レポートで紹介されている世界のフラグメントベース創薬市場のプレイヤーの属性です。 フラグメントベース創薬の世界市場レポートが回答した主要な質問 - 予測期間中の全地域におけるフラグメントベース創薬が生み出す売上高/収益は？ - 世界のフラグメントベース創薬市場におけるビジネスチャンスは？ - 市場における主な促進要因、阻害要因、機会、脅威とは？ - 予測期間中に最も速いCAGRで拡大する地域市場は？ - 2031年に世界で最も高い収益を上げると予測されるセグメントは？ - 予測期間中に最も高いCAGRで拡大すると予測されるセグメントは？ - 世界市場で事業を展開する各企業の市場ポジションは？ フラグメントベース創薬市場 - 調査目的と調査アプローチ 世界のフラグメントベース創薬市場に関する包括的なレポートは、概要から始まり、調査範囲と目的が続きます。本レポートでは、本調査の目的、市場で事業を展開する主要ベンダーと販売業者、製品承認のための規制シナリオについて詳しく解説しています。 本レポートは、読みやすさを考慮し、各セクションを章ごとに分割したレイアウトになっています。本レポートは、グラフと表を適切に配置した網羅的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化することで、読者に視覚的に訴えかけます。また、過去と予測期間末の主要セグメントの市場シェアの比較も可能です。 本レポートでは、世界のフラグメントベース創薬市場を製品、エンドユーザー、地域の観点から分析。各基準の主要セグメントを詳細に調査し、2031年末時点の各セグメントにおける市場シェアを掲載しています。このような貴重な洞察により、市場関係者は、世界のフラグメントベース創薬市場への投資について、情報に基づいたビジネス上の意思決定を行うことができます。 |
1. 序論
2. 仮定・調査方法
3. エグゼクティブサマリー
4. 市場概要
5. 主要インサイト
6. フラグメントベース創薬世界市場の分析＆予測：コンポーネント別
7. フラグメントベース創薬の世界市場分析＆予測：用途別
8. フラグメントベース創薬の世界市場分析＆予測：エンドユーザー別
9. フラグメントベース創薬の世界市場分析＆予測：地域別
10. 北米のフラグメントベース創薬世界市場の分析＆予測
11. ヨーロッパのフラグメントベース創薬世界市場の分析＆予測
12. アジア太平洋地域のフラグメントベース創薬の世界市場の分析＆予測
13. 中南米のフラグメントベース創薬世界市場の分析＆予測
14. 中東・アフリカのフラグメントベース創薬の世界市場の分析＆予測
15. 競争状況
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Fragment Based Drug Discovery Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Fragment Based Drug Discovery Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Technological Advancements
5.2. Key Industry Events
5.3. Regulatory Scenario by Region/Globally
5.4. Major Research Institutes Involved
5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Fragment Based Drug Discovery Market Analysis and Forecast, by Component
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Component, 2017-2031
6.3.1. Fragment Screening
6.3.1.1. Biophysical Techniques
6.3.1.1.1. NMR Spectroscopy
6.3.1.1.2. Differential Scanning Fluorimetry (DSF) Assay
6.3.1.1.3. Fluorescence Polarization
6.3.1.1.4. Isothermal Titration Calorimetry
6.3.1.1.5. X-ray Crystallography
6.3.1.1.6. Surface Plasmon Resonance (SPR)
6.3.1.1.7. Bilayer Interferometry
6.3.1.1.8. Mass Spectrometry (MS)
6.3.1.1.9. Capillary Electrophoresis
6.3.1.1.10. Weak Affinity Chromatography (WAC – HPLC-UV/MS)
6.3.1.1.11. Other Assays (Biochemical)
6.3.1.2. Non-biophysical Techniques
6.3.2. Fragment Optimization
6.4. Market Attractiveness Analysis, by Component
7. Global Fragment Based Drug Discovery Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2017-2031
7.3.1. Oncology
7.3.2. Central Nervous System (CNS) Disorders
7.3.3. Infectious Diseases
7.3.4. Cardiovascular Diseases
7.3.5. Metabolic Disorders
7.3.6. Inflammation & Autoimmune Diseases
7.4. Market Attractiveness Analysis, by Application
8. Global Fragment Based Drug Discovery Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017-2031
8.3.1. Academic & Research Institutions
8.3.2. Pharmaceutical & Biotechnology Companies
8.3.3. Contract Research Organizations (CROs)
8.4. Market Attractiveness Analysis, by End-user
9. Global Fragment Based Drug Discovery Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017-2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Global Fragment Based Drug Discovery Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Component, 2017-2031
10.2.1. Fragment Screening
10.2.1.1. Biophysical Techniques
10.2.1.1.1. NMR Spectroscopy
10.2.1.1.2. Differential Scanning Fluorimetry (DSF) Assay
10.2.1.1.3. Fluorescence Polarization
10.2.1.1.4. Isothermal Titration Calorimetry
10.2.1.1.5. X-ray Crystallography
10.2.1.1.6. Surface Plasmon Resonance (SPR)
10.2.1.1.7. Bilayer Interferometry
10.2.1.1.8. Mass Spectrometry (MS)
10.2.1.1.9. Capillary Electrophoresis
10.2.1.1.10. Weak Affinity Chromatography (WAC – HPLC-UV/MS)
10.2.1.1.11. Other Assays (Biochemical)
10.2.1.2. Non-biophysical Techniques
10.2.2. Fragment Optimization
10.3. Market Value Forecast, by Application, 2017-2031
10.3.1. Oncology
10.3.2. Central Nervous System (CNS) Disorders
10.3.3. Infectious Diseases
10.3.4. Cardiovascular Diseases
10.3.5. Metabolic Disorders
10.3.6. Inflammation & Autoimmune Diseases
10.4. Market Value Forecast, by End-user, 2017-2031
10.4.1. Academic & Research Institutions
10.4.2. Pharmaceutical & Biotechnology Companies
10.4.3. Contract Research Organizations (CROs)
10.5. Market Value Forecast, by Country, 2017-2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Component
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Europe Global Fragment Based Drug Discovery Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Component, 2017-2031
11.2.1. Fragment Screening
11.2.1.1. Biophysical Techniques
11.2.1.1.1. NMR Spectroscopy
11.2.1.1.2. Differential Scanning Fluorimetry (DSF) Assay
11.2.1.1.3. Fluorescence Polarization
11.2.1.1.4. Isothermal Titration Calorimetry
11.2.1.1.5. X-ray Crystallography
11.2.1.1.6. Surface Plasmon Resonance (SPR)
11.2.1.1.7. Bilayer Interferometry
11.2.1.1.8. Mass Spectrometry (MS)
11.2.1.1.9. Capillary Electrophoresis
11.2.1.1.10. Weak Affinity Chromatography (WAC – HPLC-UV/MS)
11.2.1.1.11. Other Assays (Biochemical)
11.2.1.2. Non-biophysical Techniques
11.2.2. Fragment Optimization
11.3. Market Value Forecast, by Application, 2017-2031
11.3.1. Oncology
11.3.2. Central Nervous System (CNS) Disorders
11.3.3. Infectious Diseases
11.3.4. Cardiovascular Diseases
11.3.5. Metabolic Disorders
11.3.6. Inflammation & Autoimmune Diseases
11.4. Market Value Forecast, by End-user, 2017-2031
11.4.1. Academic & Research Institutions
11.4.2. Pharmaceutical & Biotechnology Companies
11.4.3. Contract Research Organizations (CROs)
11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Component
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Global Fragment Based Drug Discovery Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Component, 2017-2031
12.2.1. Fragment Screening
12.2.1.1. Biophysical Techniques
12.2.1.1.1. NMR Spectroscopy
12.2.1.1.2. Differential Scanning Fluorimetry (DSF) Assay
12.2.1.1.3. Fluorescence Polarization
12.2.1.1.4. Isothermal Titration Calorimetry
12.2.1.1.5. X-ray Crystallography
12.2.1.1.6. Surface Plasmon Resonance (SPR)
12.2.1.1.7. Bilayer Interferometry
12.2.1.1.8. Mass Spectrometry (MS)
12.2.1.1.9. Capillary Electrophoresis
12.2.1.1.10. Weak Affinity Chromatography (WAC – HPLC-UV/MS)
12.2.1.1.11. Other Assays (Biochemical)
12.2.1.2. Non-biophysical Techniques
12.2.2. Fragment Optimization
12.3. Market Value Forecast, by Application, 2017-2031
12.3.1. Oncology
12.3.2. Central Nervous System (CNS) Disorders
12.3.3. Infectious Diseases
12.3.4. Cardiovascular Diseases
12.3.5. Metabolic Disorders
12.3.6. Inflammation & Autoimmune Diseases
12.4. Market Value Forecast, by End-user, 2017-2031
12.4.1. Academic & Research Institutions
12.4.2. Pharmaceutical & Biotechnology Companies
12.4.3. Contract Research Organizations (CROs)
12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Component
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Global Fragment Based Drug Discovery Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Component, 2017-2031
13.2.1. Fragment Screening
13.2.1.1. Biophysical Techniques
13.2.1.1.1. NMR Spectroscopy
13.2.1.1.2. Differential Scanning Fluorimetry (DSF) Assay
13.2.1.1.3. Fluorescence Polarization
13.2.1.1.4. Isothermal Titration Calorimetry
13.2.1.1.5. X-ray Crystallography
13.2.1.1.6. Surface Plasmon Resonance (SPR)
13.2.1.1.7. Bilayer Interferometry
13.2.1.1.8. Mass Spectrometry (MS)
13.2.1.1.9. Capillary Electrophoresis
13.2.1.1.10. Weak Affinity Chromatography (WAC – HPLC-UV/MS)
13.2.1.1.11. Other Assays (Biochemical)
13.2.1.2. Non-biophysical Techniques
13.2.2. Fragment Optimization
13.3. Market Value Forecast, by Application, 2017-2031
13.3.1. Oncology
13.3.2. Central Nervous System (CNS) Disorders
13.3.3. Infectious Diseases
13.3.4. Cardiovascular Diseases
13.3.5. Metabolic Disorders
13.3.6. Inflammation & Autoimmune Diseases
13.4. Market Value Forecast, by End-user, 2017-2031
13.4.1. Academic & Research Institutions
13.4.2. Pharmaceutical & Biotechnology Companies
13.4.3. Contract Research Organizations (CROs)
13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Component
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Global Fragment Based Drug Discovery Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Component, 2017-2031
14.2.1. Fragment Screening
14.2.1.1. Biophysical Techniques
14.2.1.1.1. NMR Spectroscopy
14.2.1.1.2. Differential Scanning Fluorimetry (DSF) Assay
14.2.1.1.3. Fluorescence Polarization
14.2.1.1.4. Isothermal Titration Calorimetry
14.2.1.1.5. X-ray Crystallography
14.2.1.1.6. Surface Plasmon Resonance (SPR)
14.2.1.1.7. Bilayer Interferometry
14.2.1.1.8. Mass Spectrometry (MS)
14.2.1.1.9. Capillary Electrophoresis
14.2.1.1.10. Weak Affinity Chromatography (WAC – HPLC-UV/MS)
14.2.1.1.11. Other Assays (Biochemical)
14.2.1.2. Non-biophysical Techniques
14.2.2. Fragment Optimization
14.3. Market Value Forecast, by Application, 2017-2031
14.3.1. Oncology
14.3.2. Central Nervous System (CNS) Disorders
14.3.3. Infectious Diseases
14.3.4. Cardiovascular Diseases
14.3.5. Metabolic Disorders
14.3.6. Inflammation & Autoimmune Diseases
14.4. Market Value Forecast, by End-user, 2017-2031
14.4.1. Academic & Research Institutions
14.4.2. Pharmaceutical & Biotechnology Companies
14.4.3. Contract Research Organizations (CROs)
14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Component
14.6.2. By Application
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. Alveus Pharmaceuticals Pvt. Ltd.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Astex Pharmaceuticals
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Charles River Laboratories International, Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Beactica AB
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Emerald BioStructures, Inc.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Crown Bioscience, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Evotec AG
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Proteros Fragments GmbH
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Kinetic Discovery Limited
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. Sprint Bioscience
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. Sygnature Discovery
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
15.3.12. Structure Based Design, Inc.
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Product Portfolio
15.3.12.3. Financial Overview
15.3.12.4. SWOT Analysis
15.3.12.5. Strategic Overview
Table 01: Global Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Component, 2017-2031
Table 02: Global Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Application, 2017-2031
Table 03: Global Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by End-user, 2017-2031
Table 04: Global Fragment Based Drug Discovery Market Size (US$ Million) Forecast, by Region, 2017-2031
Table 05: North America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Country, 2017-2031
Table 06: North America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Component, 2017-2031
Table 07: North America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Application, 2017-2031
Table 08: North America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by End-user, 2017-2031
Table 09: Europe Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Country/Sub-region, 2017-2031
Table 10: Europe Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Component, 2017-2031
Table 11: Europe Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Application, 2017-2031
Table 12 Europe Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by End-user, 2017-2031
Table 13: Asia Pacific Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Country/Sub-region, 2017-2031
Table 14: Asia Pacific Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Component, 2017-2031
Table 15: Asia Pacific Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Application, 2017-2031
Table 16: Asia Pacific Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by End-user, 2017-2031
Table 17: Latin America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Country/Sub-region, 2017-2031
Table 18: Latin America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Component, 2017-2031
Table 19: Latin America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Application, 2017-2031
Table 20: Latin America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by End-user, 2017-2031
Table 21: Middle East & Africa Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Country/Sub-region, 2017-2031
Table 22: Middle East & Africa Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Component, 2017-2031
Table 23: Middle East & Africa Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Application, 2017-2031
Table 24: Middle East & Africa Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by End-user, 2017-2031